We serve Chemical Name:methyl (-)-(S)-tanshinonate CAS:18887-19-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:methyl (-)-(S)-tanshinonate
CAS.NO:18887-19-9
Synonyms:(S)-1,6-Dimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydro-phenanthro[1,2-b]furan-6-carboxylic acid methyl ester;methyl tanshinonate
Molecular Formula:C20H18O5
Molecular Weight:338.35400
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:73.58000
Exact Mass:338.11500
LogP:3.40100
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like (S)-1,6-Dimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydro-phenanthro[1,2-b]furan-6-carboxylic acid methyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methyl tanshinonate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,methyl tanshinonate Use and application,(S)-1,6-Dimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydro-phenanthro[1,2-b]furan-6-carboxylic acid methyl ester technical grade,usp/ep/jp grade.
Related News: Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL. methyl (-)-(S)-tanshinonate manufacturer Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL. methyl (-)-(S)-tanshinonate supplier Rigosertib, Onconova��s lead candidate, is a proprietary Phase 3 small molecule. methyl (-)-(S)-tanshinonate vendor Compared to white women, Black women are more likely to be diagnosed with breast cancer before age 50 or with estrogen receptor (ER)-negative and triple-negative breast cancer. methyl (-)-(S)-tanshinonate factory Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL.
